$PPHM News Peregrine plunges on test data 3:17 p.m. June

New Post Public Reply Private Reply Replies (0) Message Board

Jan 7, 2014 at 12:55 PM

$PPHM News

Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid

eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 3:23 p.m. May 21, 2012 - MarketWatch

Peregrine Pharmaceuticals (PPHM) Soars: Stock Adds 14.5% in Session - Tale of the Tape 8:57 a.m. Today - Zacks.com
Why Peregrine Pharmaceuticals (PPHM) is Surging 10:41 a.m. Jan. 6, 2014 - TheStreet.com
Peregrine Pharma Initiates Bavituximab Study - Analyst Blog 5:20 p.m. Dec. 31, 2013 - Zacks.com
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 6:37 a.m. Dec. 30, 2013 - benzinga.com
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers 10:28 a.m. Dec. 23, 2013 - TheStreet.com
Peregrine Reports In-Line Loss - Analyst Blog 2:10 p.m. Dec. 11, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q2 2014 Results - Earnings Call Transcript 7:20 p.m. Dec. 10, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 5:34 p.m. Dec. 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape 9:39 a.m. Nov. 22, 2013 - Zacks.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma 8:10 a.m. Nov. 8, 2013 - benzinga.com
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape 7:06 a.m. Nov. 8, 2013 - Zacks.com
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals' CEO Hosts Annual Meeting of Stockholders (Transcript) 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Peregrine Pharmaceuticals, Inc. - Shareholder/Analyst Call 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Biotech: Let's Make A Billion-Dollar Deal, Part 2 2:00 p.m. Oct. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now 8:58 a.m. Sept. 10, 2013 - Wall St. Cheat Sheet
Peregrine Reports In-Line Loss - Analyst Blog 8:30 a.m. Sept. 10, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q1 2014 Results - Earnings Call Transcript 6:10 p.m. Sept. 9, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:24 p.m. Sept. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)

Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer 7:30 a.m. Jan. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 7:31 a.m. Dec. 30, 2013 - Marketwire
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments 4:00 p.m. Dec. 10, 2013 - Marketwire
Peregrine Pharmaceuticals Announces Upcoming Events 4:00 p.m. Nov. 26, 2013 - Marketwire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR 10:35 a.m. Nov. 11, 2013 - ACCESSWIRE
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 9:01 a.m. Nov. 8, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 3:03 p.m. Oct. 31, 2013 - PR Newswire
Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target 7:31 a.m. Oct. 15, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 10:25 a.m. Oct. 9, 2013 - PR Newswire
Record Use of At-the-Market (ATM) Offerings by U.S. Life Sciences Companies in First Half of 2013, Reports Brinson Patrick 7:00 a.m. Sept. 17, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments 3:00 p.m. Sept. 9, 2013 - Marketwire
Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 7:31 a.m. Sept. 9, 2013 - Marketwire
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. 4:11 p.m. Sept. 6, 2013 - PR Newswire
Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013 3:06 p.m. Sept. 3, 2013 - Marketwire
Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference 2:01 p.m. Aug. 14, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Upcoming Conferences 3:00 p.m. Aug. 6, 2013 - Marketwire
Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma 8:12 a.m. July 31, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments 3:06 p.m. July 11, 2013 - Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quanta Services Reports Record Q3 2026 Earnings

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Faith on Trial: La Luz del Mundo Faces Court Ruling

A Legal Battle Over Religious Freedom When folks start talking about religion intertwining with law, things get real tricky, real quick. The La Luz del Mundo church is knee-deep in such a legal tussle. On October 28, 2026, the United States District Court for the Southern District of New York gave a nod to the prosecution, denying the church's pretrial motions. What we've...

2026 Data Integration Stars: User Sentiments Revealed

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Banco Macro S.A. Plans $160B Share Buyback Initiative

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Smartpress: Adobe & Canva Shape Print Design World

Adobe's Stranglehold on Professional Design Over at Smartpress, they've pulled the curtain back on just how heavily Adobe Creative Suite weighs in on the print design sector. The company's recent analysis shines a light on the staggering 66% dominance of Adobe's InDesign and Illustrator in file submissions. That's a hefty portion influencing both the quality and financial...

Atlantic Blvd Apartments: A Game-Changer for Housing

A Bold Move for Attainable Housing Amidst the hustle and bustle of Sterling, Virginia, a new player has hit the scene: Atlantic Blvd Apartments. A property designed solely for attainable housing, this development is a showcase of what can be accomplished when local government and private developers team up with a shared vision. It feels like a breath of fresh air in a...

Data Breach at Lumara Bio: Privacy Lawsuits Loom

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Infection Control Market Set for Explosive Growth by 2031

Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...

Genefluence Launches Rapid UTI PCR Test at Chelsea Hospital

There's a fresh breeze blowing through the dusty corridors of healthcare, shaking things up for the better. You see, Genefluence, the brainchild of Professor Chris Toumazou, isn't just throwing a bunch of tech jargon around—it's setting the stage for a much-needed shake-up in how we handle urinary tract infections (UTIs) and, believe me, it couldn’t have come sooner....